Current neuropharmacology · 2025
Co-administration of Naringin and NLRP3 Inhibitor Improves Myelin Repair and Mitigates Oxidative Stress in Cuprizone-Induced Demyelination Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kalaki-Jouybari Fatemeh, Shirzad Moein, Javan Mohammad, Ghasemi-Kasman Maryam, Pouramir Mehdi
Аннотация
BACKGROUND: Naringin and MCC950 as an inflammasome inhibitor have exhibited numerous pharmacological activities, including antioxidant and anti-inflammatory effects. The present study has examined the combined impacts of naringin and MCC950 on the levels of oxidative stress, demyelination, and inflammation in the cuprizone (CPZ)-induced demyelination model.
METHODS: In order to induce demyelination, CPZ (0.2% w/w) was added to the normal diet of mice for 42 days. Subsequently, the male C57BL/6 mice received naringin (oral administration), MCC950 (intraperitoneal injection), or their combination for 14 days. Working memory was tested by the Y maze. FluoroMyelin staining, MOG, and GFAP immunostaining assessed the demyelination extent, myelin intensity, and astrocyte activation, respectively. Oxidant/antioxidant biomarkers were measured using colorimetric techniques. The expression levels of MBP, PDGFRα, Olig2, Nrf2, HO-1, NQO-1, GSK3β, IL1α, and IL18 were assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RESULTS: Our results indicated that the co-administration of naringin and MCC950 improved working memory and antioxidant capacity. A significant reduction was found in the extent of demyelination and inflammatory mediatorsin naringin and MCC950-treated mice. In addition, co-administration of naringin and MCC950 elevated the expression levels of pro-myelinating and antioxidant markers.
CONCLUSION: These findings indicated improvement of the working memory through co-administration of naringin and MCC950, which might be partly mediated by enhancing antioxidant capacity, promoting remyelination, and mitigating inflammation in the CPZ-induced demyelination model.
METHODS: In order to induce demyelination, CPZ (0.2% w/w) was added to the normal diet of mice for 42 days. Subsequently, the male C57BL/6 mice received naringin (oral administration), MCC950 (intraperitoneal injection), or their combination for 14 days. Working memory was tested by the Y maze. FluoroMyelin staining, MOG, and GFAP immunostaining assessed the demyelination extent, myelin intensity, and astrocyte activation, respectively. Oxidant/antioxidant biomarkers were measured using colorimetric techniques. The expression levels of MBP, PDGFRα, Olig2, Nrf2, HO-1, NQO-1, GSK3β, IL1α, and IL18 were assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RESULTS: Our results indicated that the co-administration of naringin and MCC950 improved working memory and antioxidant capacity. A significant reduction was found in the extent of demyelination and inflammatory mediatorsin naringin and MCC950-treated mice. In addition, co-administration of naringin and MCC950 elevated the expression levels of pro-myelinating and antioxidant markers.
CONCLUSION: These findings indicated improvement of the working memory through co-administration of naringin and MCC950, which might be partly mediated by enhancing antioxidant capacity, promoting remyelination, and mitigating inflammation in the CPZ-induced demyelination model.